Apexigen, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APGN research report →
Price Chart
About the company
Apexigen Inc. , established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates.
- CEO
- Xiaodong Yang
- IPO
- 2021
- Employees
- 11
- HQ
- San Carlos, CA, US
Get TickerSpark's AI analysis on APGN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.57M
- P/E
- -0.24
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 1.19
- EV/EBITDA
- 0.16
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 48.27%
- ROIC
- -493.64%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-32,686,000
- Net Income
- $-31,452,000-8.9%
- EPS
- $-1.59-71.0%
- OCF Growth
- -28.4%
- FCF Growth
- -28.4%
- 52W High
- $8.28
- 52W Low
- $0.33
- 50D MA
- $0.43
- 200D MA
- $0.92
- Beta
- 3.62
- RSI (14)
- 44
- Avg Volume
- 262.33K
No earnings-call transcripts are available for APGN yet.
- Free Float
- 88.8%
- Shares Outstanding
- 24.86M
- Float Shares
- 22.08M
Buy/sell ratio 0.02. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 23, 23 | Zabrowksi Dan | sell | 100,000 |
| Aug 23, 23 | Wertheimer Samuel P | sell | 1,845 |
| Aug 23, 23 | Wertheimer Samuel P | sell | 146,383 |
| Aug 23, 23 | Wertheimer Samuel P | sell | 100,000 |
| Aug 23, 23 | Wertheimer Samuel P | sell | 12,383 |
| Aug 23, 23 | Smith Scott Andrew | sell | 34,084 |
| Aug 23, 23 | Smith Scott Andrew | sell | 100,000 |
| Aug 23, 23 | RINGOLD GORDON | sell | 5,000 |
| Aug 23, 23 | RINGOLD GORDON | sell | 100,000 |
| Aug 23, 23 | RINGOLD GORDON | sell | 10,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APGN coverage
Recent articles, reports, and earnings notes.
No research on APGN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APGN report →APEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
businesswire.com · Aug 10
Apexigen Announces Phase 2 Data Evaluating Sotigalimab, its CD40 Agonist Antibody, in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma Presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
globenewswire.com · Jun 3
APEXIGEN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc. - APGN
businesswire.com · May 30
Apexigen (APGN) to Get Acquired by Pyxis Oncology, Stock Up
zacks.com · May 25
Shareholder Alert: Ademi LLP investigates whether Apexigen, Inc. has obtained a Fair Price in its transaction with Pyxis Oncology
prnewswire.com · May 24
Why Is Apexigen (APGN) Stock Up 31% Today?
investorplace.com · May 24
APGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to Shareholders
businesswire.com · May 24
APGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to Shareholders
businesswire.com · May 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.